Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 1.4% – Here’s Why

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Get Free Report) traded down 1.4% on Wednesday . The stock traded as low as $0.2250 and last traded at $0.2251. 209,065 shares were traded during trading, a decline of 67% from the average session volume of 633,613 shares. The stock had previously closed at $0.2284.

Theriva Biologics Trading Down 1.8%

The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $7.45 million, a PE ratio of -0.01 and a beta of 1.11. The stock has a 50 day moving average price of $0.25 and a 200-day moving average price of $0.24.

Get Theriva Biologics alerts:

Theriva Biologics (NYSEAMERICAN:TOVX – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.05) EPS for the quarter. The company had revenue of $0.30 million during the quarter.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently raised its position in Theriva Biologics stock. Geode Capital Management LLC increased its holdings in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX – Free Report) by 651.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 212,087 shares of the company’s stock after buying an additional 183,878 shares during the quarter. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 at the end of the most recent reporting period. Institutional investors own 6.17% of the company’s stock.

About Theriva Biologics

(Get Free Report)

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.

See Also

• Five stocks we like better than Theriva Biologics
• Datadog’s Drop Says More About Expectations Than Earnings
• D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
• Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
• Solventum Nears Inflection Point As It Begins to Unlock Value

Receive News & Ratings for Theriva Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theriva Biologics and related companies with MarketBeat.com's FREE daily email newsletter.